- Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha2021 | Third Faculty of Medicine
- Anti-tumour necrosis factor treatment of severe psoriasis complicated by Epstein-Barr Virus hepatitis and subsequently by chronic hepatitis2015 | Faculty of Medicine in Pilsen
- Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors +1First Faculty of Medicine, Second Faculty of Medicine
- Biological treatment of Idiopathic inflammatory bowel diseases2015 | First Faculty of Medicine
- Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease2021 | Second Faculty of Medicine
- A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study2016 | First Faculty of Medicine
- Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN2017 | Second Faculty of Medicine
- Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort2019 | Faculty of Medicine in Pilsen
- The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update2021 | Second Faculty of Medicine
- First experience of vedolizumab in paediatric IBD patients +12019 | Second Faculty of Medicine
- Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease2019 | First Faculty of Medicine, Central Library of Charles University
- Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study2022 | First Faculty of Medicine
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial2017 | First Faculty of Medicine, Central Library of Charles University
- 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial2020 | First Faculty of Medicine